Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 11
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma.
Pratedrat P, Intharasongkroh D, Chansaenroj J, Vichaiwattana P, Srimuan D, Thatsanatorn T, Klinfueng S, Nilyanimit P, Chirathaworn C, Kupatawintu P, Chaiwanichsiri D, Wanlapakorn N, Poovorawan Y. Pratedrat P, et al. Among authors: thatsanatorn t. Diseases. 2023 Aug 30;11(3):112. doi: 10.3390/diseases11030112. Diseases. 2023. PMID: 37754308 Free PMC article.
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
Wanlapakorn N, Kanokudom S, Phowatthanasathian H, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, Vichaiwattana P, Klinfueng S, Thongmee T, Aeemjinda R, Khanarat N, Srimuan D, Thatsanatorn T, Chantima W, Pakchotanon P, Duangchinda T, Sudhinaraset N, Poovorawan Y. Wanlapakorn N, et al. Among authors: thatsanatorn t. J Med Virol. 2023 May;95(5):e28758. doi: 10.1002/jmv.28758. J Med Virol. 2023. PMID: 37212319
SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.
Suntronwong N, Vichaiwattana P, Klinfueng S, Puenpa J, Kanokudom S, Assawakosri S, Chansaenroj J, Srimuan D, Thatsanatorn T, Songtaisarana S, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Suntronwong N, et al. Among authors: thatsanatorn t. PLoS One. 2023 Apr 27;18(4):e0279147. doi: 10.1371/journal.pone.0279147. eCollection 2023. PLoS One. 2023. PMID: 37104299 Free PMC article.
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens.
Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, Aeemjinda R, Khanarat N, Vichaiwattana P, Klinfueng S, Thongmee T, Katanyutanon A, Thanasopon W, Arayapong J, Withaksabut W, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y. Kanokudom S, et al. Among authors: thatsanatorn t. Int J Infect Dis. 2023 Jan;126:64-72. doi: 10.1016/j.ijid.2022.11.022. Epub 2022 Nov 22. Int J Infect Dis. 2023. PMID: 36427701 Free PMC article.
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine.
Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Mongkolsapaya J, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y. Kanokudom S, et al. Among authors: thatsanatorn t. Vaccine. 2022 Sep 16;40(39):5657-5663. doi: 10.1016/j.vaccine.2022.08.033. Epub 2022 Aug 22. Vaccine. 2022. PMID: 36031500 Free PMC article.
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
Suntronwong N, Kanokudom S, Auphimai C, Assawakosri S, Thongmee T, Vichaiwattana P, Duangchinda T, Chantima W, Pakchotanon P, Chansaenroj J, Puenpa J, Nilyanimit P, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Poovorawan Y. Suntronwong N, et al. Among authors: thatsanatorn t. J Med Virol. 2022 Dec;94(12):5713-5722. doi: 10.1002/jmv.28044. Epub 2022 Aug 10. J Med Virol. 2022. PMID: 35924475 Free PMC article.
Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination.
Suntronwong N, Assawakosri S, Kanokudom S, Yorsaeng R, Auphimai C, Thongmee T, Vichaiwattana P, Duangchinda T, Chantima W, Pakchotanon P, Chansaenroj J, Nilyanimit P, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Poovorawan Y. Suntronwong N, et al. Among authors: thatsanatorn t. Diagnostics (Basel). 2022 Jul 22;12(8):1781. doi: 10.3390/diagnostics12081781. Diagnostics (Basel). 2022. PMID: 35892491 Free PMC article.
Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
Chansaenroj J, Suntronwong N, Kanokudom S, Assawakosri S, Yorsaeng R, Vichaiwattana P, Klinfueng S, Wongsrisang L, Srimuan D, Thatsanatorn T, Thongmee T, Auphimai C, Nilyanimit P, Wanlapakorn N, Sudhinaraset N, Poovorawan Y. Chansaenroj J, et al. Among authors: thatsanatorn t. Vaccines (Basel). 2022 Jul 3;10(7):1071. doi: 10.3390/vaccines10071071. Vaccines (Basel). 2022. PMID: 35891235 Free PMC article.
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Mongkolsapaya J, Wanlapakorn N, Honsawek S, Poovorawan Y. Assawakosri S, et al. Among authors: thatsanatorn t. Int J Infect Dis. 2022 Sep;122:793-801. doi: 10.1016/j.ijid.2022.07.038. Epub 2022 Jul 19. Int J Infect Dis. 2022. PMID: 35863731 Free PMC article.
COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron.
Suntronwong N, Yorsaeng R, Puenpa J, Auphimai C, Thongmee T, Vichaiwattana P, Kanokudom S, Duangchinda T, Chantima W, Pakchotanon P, Assawakosri S, Nilyanimit P, Klinfueng S, Wongsrisang L, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Suntronwong N, et al. Among authors: thatsanatorn t. Vaccines (Basel). 2022 Mar 3;10(3):391. doi: 10.3390/vaccines10030391. Vaccines (Basel). 2022. PMID: 35335023 Free PMC article.
14 results